anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
LN is a heterogeneous autoimmune disease that includes a broad spectrum of clinical forms, ranging from those with lesions confined to the skin (cutaneous lupus erythematosus \[CLE\]) to others that involve one or more vital internal organs (systemic lupus erythematosus \[SLE\]). Renal involvement due to SLE is termed LN. Nipocalimab (also referred to as JNJ-80202135 or M281) is a fully human aglycosylated immunoglobulin (Ig) G1 monoclonal antibody designed to selectively bind, saturate, and block the IgG binding site on the endogenous neonatal fragment crystallizable receptor (FcRn). By targeting the IgG binding site on FcRn, nipocalimab is expected to block the binding and, hence, recycling of IgG into circulation, resulting in a decrease in circulating IgG antibody levels, including pathogenic IgG autoantibodies and alloantibodies. The study will consist of a screening period (less than or equal to \[\<=\] 8 Week), double-blind treatment period (52 Week), and a safety follow-up period (6 Week). Safety assessment will include adverse events (AEs), serious adverse events (SAEs), laboratory parameters (hematology and chemistry) and vital signs. The total duration of the main study is up to 66 weeks.
Chemotherapy is widely used to treat colorectal cancer (CRC). Despite its substantial benefits, the development of drug resistance and adverse effects remain challenging. This study aimed to elucidate a novel role of glucagon in anti-cancer therapy. In a series of in vitro experiments, glucagon inhibited cell migration and tube formation in both endothelial and tumor cells. In vivo studies demonstrated decreased tumor blood vessels and fewer pseudo-vessels in mice treated with glucagon. The combination of glucagon and chemotherapy exhibited enhanced tumor inhibition. Mechanistic studies demonstrated that glucagon increased the permeability of blood vessels, leading to a pronounced disruption of vessel morphology. Signaling pathway analysis identified a VEGF/VEGFR-dependent mechanism whereby glucagon attenuated angiogenesis through its receptor. Clinical data analysis revealed a positive correlation between elevated glucagon expression and chemotherapy response. This is the first study to reveal a role for glucagon in inhibiting angiogenesis and vascular mimicry. Additionally, the delivery of glucagon-encapsulated PEGylated liposomes to tumor-bearing mice amplified the inhibition of angiogenesis and vascular mimicry, consequently reinforcing chemotherapy efficacy. Collectively, the findings demonstrate the role of glucagon in inhibiting tumor vessel network and suggest the potential utility of glucagon as a promising predictive marker for patients with CRC receiving chemotherapy.
1285932 Antimicrobial compositions containing nitrofuran derivatives CIBA-GEIGY AG 5 June 1970 [5 June 1969 28 April 1970] 28423/69 and 20274/70 Headings A5B and A5E [Also in Division C2] Antimicrobial nitrofurans of formula I: which may also be represented by the tautomeric formula IA: (in which formulae R is C 1-5  alkyl or C 2-5  hydroxyalkyl) may be mixed with pharmaceutically acceptable carriers to form pharmaceutical compositions, or added to animal feedstuffs as growth-promoting substances, or used to treat an organic material susceptible to bacterial or other microbial attack to protect the material from such attack. The organic material may be a natural or synthetic polymeric material, a proteinaceous or carbohydrate substance, or a natural or synthetic fibre or textile material prepared therefrom. The pharmaceutical compositions have antibacterial, anthelmintic, antiprotozoal, coccidiostatic, trypanocidal and antimalarial activity and may be in the form of ointments, powders, tinctures, emulsions, solutions, gargles, tablets, lozenges, dragees and capsules. The compositions may also contain other active ingredients such as sulpha drugs, chloramphenicol or tetracycline or other antibiotics, halogenated salicylanilides, carbanilides, benzoazoles or benzoxazolones, polychloro-hydroxy-diphenylmethanes, halogenhydroxydiphenyl sulphides or ethers, quaternary ammonium compounds or dithiocarbamic acid derivatives. Specific compounds are named. Carriers which themselves have pharmacological activity, e.g. zinc stearate and sulphur, may be used.
Systems, methods, and computer program products are provided for determining one or more biomarker and/or health condition of a target patient. In various embodiments, a method is provided where a plurality of health data of the target patient and/or a plurality of first order features determined from the plurality of health data of the target patient are received as input to a pre-trained artificial neural network. The plurality of health data is derived from a plurality of modalities. A plurality of latent variables based on the plurality of health data and plurality of first order features are received from an intermediate layer of the pre-trained artificial neural network. The plurality of latent variables are provided to a pre-trained learning system. The pre-trained learning system is trained to receive as input the plurality of latent variables and output one or more biomarker and/or health condition of the target patient.
<P>PROBLEM TO BE SOLVED: To provide a technique capable of preparing a report without interrupting diagnostic reading during diagnostic reading and report preparation work.  <P>SOLUTION: An image observation device displays a medial image identified by patient information and receives an input of a comment or annotation to the medical image. A data storage device associates the comment and annotation with the medical image and stores them. This report preparation support device acquires the comment or annotation from the data storage device, and extracts text. The report preparation support device previously stores a rule table for defining text arrangement and order rules and publishes the stored text in document data by the arrangement and order according to the rule table.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The purpose of this project is to combine a novel posturogrpahy based on HTC VIVE trackers and hybrid machine learning and deep learning algorithms to establish a set of simple, convenient and valid fall risk assessment tool. This observational and follow up study will community elderly aged over 60 years old. The investigators will collect demographic data, questionnaire surveys, traditional balance tests (Berg Balance scale, Timed-up-and-go, 30s-sit-to-stand, four-stage balance tests) and a tracker-based posturography to obtain the trunk stability parameters in different standing task. The fall risk will be classified according to self-reported falls in the past one year and verified in a 6-month follow up.

The investigators will evaluate the performance of different hybrid machine learning and deep learning algorithm to extract the important features of multiple posturographic parameters and select an optimal model. The investigators will use the receiver operating characteristic curve analysis to compute the sensitivity, specificity and accuracy of different algorithms for risk classification and also compare the performance with traditional balance assessment tools. The investigators will evaluate the correlation of these posturographic features and data obtained by other methods. Risk factors of previous falls and future falls will also analyzed.
This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 4-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
FIELD: cosmetics. SUBSTANCE: vitamin D in amount of 0.1-0.5 mas.pts per 1000 mas. pts of composition is introduced in cosmetic base. Preliminarily dissolved in water hyaluronic acid, and angelicine dissolved in alcohol are additionally introduced in preparation in amount of 0.1-0.3 mas.pts and 0.5-1 mas.pts, respectively. EFFECT: prolonged action of preparation. 1 tbl
Polyclonal immunoglobulin-based intravenous preparation for the therapy and prophylaxis of bacterial infections, which contains at least 50% by weight of IgM, based on the total immunoglobulin content, and has a low anticomplementary activity, and is stable in aqueous solution and free of viruses. It can also consist of a mixture of several monoclonal IgM antibodies or contain such in addition. Preparation starts from an immunoglobulin-containing fraction of human, animal or bacterial origin. The fraction is treated with an anion exchanger, the latter is eluted with a salt or pH gradient, and the eluate is subjected, where appropriate, to a gel filtration. The chromatography is preceded or followed by a treatment with  beta -propiolactone and PEG 4000 and, where appropriate, heating. It is additionally possible to carry out a treatment with  beta -propiolactone and UV light, with detergents or a pasteurisation. Proteins, sugars or amino acid mixtures can, where appropriate, be added to the preparation.
The invention relates to a method for extracting the total flavonoids of bidens bipinnata (TFB) and an application of the TFB in the preparation of a medicine for treating rheumatoid arthritis. The method for extracting the TFB comprises the following steps of: taking the bidens bipinnata, dissolving by ethanol and extracting; collecting extract, and adsorbing by a macroporous resin; washing by water to remove impurities, and eluting by ethano; and measuring the content and the yield of the total flavonoids in the solution of the TFB by adopting the colorimetric method. By adsorbing and eluting under the condition, the macroporous resin can be reused. After adsorbing by the macroporous resin and desorbing by the ethanol, the solution of the TFB can be obtained. 80-160mg/kg of solution of the TFB is taken for treating rheumatoid arthritis. The new medicinal prospect of the TFB is excavated, and the effect of the TFB on treating rheumatoid arthritis is definite. The prepared TFB is taken orally and conveniently, has low toxic and side effects and can not cause harm to the human body after being taken for a long time.
BACKGROUND: Pulmonary emphysema is a part of chronic obstructive pulmonary disease, which is an irreversible chronic respiratory disease. In order to avoid further damage to lung tissue, early diagnosis and treatment of pulmonary emphysema is essential.
PURPOSE: Early pulmonary emphysema diagnosis is difficult with conventional radiographic imaging. Recently, x-ray phase contrast imaging has proved to be an effective and promising imaging strategy for soft tissue, due to its high sensitivity and multi-contrast. The aim of this study is to diagnose pulmonary emphysema early utilizing an x-ray Talbot-Lau interferometer (TLI).
METHODS: We successfully established the mouse model of emphysema by porcine pancreatic elastase treatment, and then used the established x-ray TLI to perform imaging experiments on the mice with different treatment time. The traditional absorption CT and phase contrast CT were obtained simultaneously through TLI. The CT results and histopathology of mice lung in different treatment time were quantitatively analyzed.
RESULTS: By imaging mice lungs, it can be found that phase contrast has higher sensitivity than absorption contrast in early pulmonary emphysema. The results show that the phase contrast signal could distinguish the pulmonary emphysema earlier than the conventional attenuation signal, which can be consistent with histological images. Through the quantitative analysis of pathological section and phase contrast CT, it can be found that there is a strong linear correlation.
CONCLUSIONS: In this study, we quantitatively analyze mean linear intercept of histological sections and CT values of mice. The results show that the phase contrast signal has higher imaging sensitivity than the attenuation signal. X-ray TLI multi-contrast imaging is proved as a potential diagnostic method for early pulmonary emphysema in mice.
One suppository in the rectum morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to the response of the individual case.

All prescription substitutions and/or recommendations using this product shall be made subject to state and federal statutes as applicable. Please NOTE: This is not an Orange Book product and has not been subjected to FDA therapeutic or other equivalency testing. No representation is made as to generic status or bioequivalency. Each person recommending a prescription substitution using this product shall make such recommendation based on his/her professional knowledge and opinion, upon evaluating the active ingredients, inactive ingredients, excipients and chemical information provided herein.
Current hypothesis of the mechanism of atrial fibrillation (AF) is a combination of local firing mainly triggered from the pulmonary veins and atrial substrate due to atrial remodelling sustaining AF. Whereas for paroxysmal AF, pulmonary vein isolation (PVI) is still the mainstay of interventional treatment, a left atrial (LA) substrate-based ablation especially in patients with persistent or long-standing persistent AF may be reasonable to improve freedom from AF. In addition, even in patients with paroxysmal AF, substrate-based ablation strategies have been shown to improve outcome. Substrate characterization of the LA is currently performed using the focal ablation catheter with a 3.5mm irrigated tip catheter with a 2 mm interelectrode spacing, a circular (Lasso) or spider like diagnostic (Pentaray) catheter with 1 mm size of the ring electrodes and 2 mm to 4 mm interelectrode spacing. Consequently, the cut-off values to delineate healthy tissue from diseased substrate are defined based on these measures. Since the electrode size and distance between the electrodes determines the bipolar voltage amplitude and morphology (beside their orientation with regard to the propagation wavefront), differences in bipolar voltage values must be expected between different catheter types and especially for the novel micro-electrode catheters IntellaMap Orion and IntellaNav MIFI OI. With the knowledge of the relationship between the bipolar voltage maps created with the different catheter types, information/knowledge from one study obtained with a specific catheter can be transferred to patients treated with the other catheter types. This study is to investigate the correlation and to obtain the coefficient of correlation between the global and local bipolar signals (voltage maps) of the LA in sinus rhythm using a focal 4.5 mm irrigated-tip ablation catheter (in combination with microelectrodes), a ring-electrode circular mapping catheter and a microelectrode multipolar catheter in combination with the Rhythmia system.
INTRODUCTION: Cauda equina neuroendocrine tumors (CENETs), previously described as cauda equina paragangliomas (PGLs) are rare and well-vascularized benign entities which can be often misdiagnosed with other intradural tumors more common in this anatomical site, such as ependymomas and neurinomas. We describe three cases of CENETs observed at our institution with particular focus on differential diagnosis and postoperative management. Since the lack of guidelines, we performed a literature review to identify factors that can predict recurrence and influence postoperative decision making.
CASE REPORT AND LITERATURE REVIEW: We report on three patients, two of them presenting with a clinical history of lower back pain and sciatica. In all cases magnetic resonance imaging (MRI) of the lumbosacral spine with and without Gd-DTPA revealed an intradural lesion with strong contrast enhancement, first described as atypical ependymoma or schwannoma. A complete tumor resection was achieved in all cases, the histopathological diagnosis classified the tumors as CENETs. In our literature review, a total of 688 articles were screened and 162 patients were included. Patients demographic data, clinical symptoms, resection and recurrence were recorded.
DISCUSSION: Differential diagnosis between CENETs and other more common tumors affecting cauda equina region, such as ependymomas or schwannomas (neurinomas), is still very challenging. Due to the lack of specific clinical or radiological characteristics, a correct preoperative diagnosis is almost impossible. With this paper we want to point out that CENETs must be considered in the differential diagnosis, most of all in case of entities with atypical radiological features. According to the literature, tumor recurrence after gross total resection is unlikely, while a long-term follow-up is recommended in case of subtotal resection or local aggressive behavior.
A complex community of microbes collectively referred to as microbiota, inhabit the human body. The intestinal microbiota is a diverse and dynamic ecosystem, which has developed a mutualistic relationship with its host and plays a crucial role in the development of the host's innate and adaptive immune responses. This ecosystem serves the host by protecting against pathogens, harvesting otherwise inaccessible nutrients, aiding in neutralization of drugs and carcinogens, and affecting the metabolism of lipids. Gut bacteria modulate intestinal motility, barrier function and visceral perception. A better understanding of the role of microbiota in the proposed GI diseases will have profound impact in the characterization of future biomarkers and has also potential treatment implications. As the microbiota may be disturbed in the mentioned GI conditions, a possible treatment approach could be to correct dysbiosis either by the administration of an antibiotic or a preparation of 'beneficial' bacteria (probiotics) according to each bacteria profile.

General Objective The objective of this study is to identify different patterns of intestinal microbiota in patients diagnosed with inflammatory bowel disease, microscopic colitis, functional diarrhea, severe motility disorders, celiac disease and irritable bowel syndrome and to compare it with non-disease controls, by assessing data (questionnaires) and samples (stool, blood and tissue) from single time point (endoscopy/colonoscopy appointment).
Currently, the most commonly employed adjunct to peripheral nerve blockade is perineural dexamethasone. In general, at the doses used in regional anesthesia, dexamethasone has a minimal side effect profile. However, while it has been shown to increase duration of analgesia, there have been concerns regarding its neurotoxicity in animal studies. In addition, dexamethasone has the potential to cause hyperglycemia in patients with impaired glucose metabolism as well as perineal pain and pruritis when administered peripherally.

Dexmedetomidine is a highly selective alpha-2 agonist that is commonly used in patients undergoing anesthesia or requiring sedation in a non-operative setting. As a peripherally administered medication, it has both sedating and analgesic properties, as well as the added benefit of avoidance of respiratory depression. Although it can rarely produce cardiac depression at high doses, its side effect profile is otherwise minimal and is generally very well tolerated by most patients. When administered peripherally, dexmedetomidine has most commonly been associated with side effects such as hypotension, respiratory depression, and bradycardia - although all at significantly higher doses than planned in our study. The safe use of perineural dexmedetomidine together with local anesthetics has been described on numerous occasions. Nevertheless, although it has been shown to potentiate peripheral nerve blockade and prolong duration of analgesia in various studies , it remains rarely used as an adjunct to regional anesthesia.
A four session program, each last for 2.5 hours. It promotes the coping and problem solving of caregivers. Brief home application included.
The invention relates to a drug for curing rheumatic disease, in particular to a Chinese patent drug prepared by taking Chinese medicinal herb as raw materials. The invention also relates to a method for preparing the drug. The drug takes suncured ginseng, cassia twig, divaricate saposhnikovia root, rhynohophylla, alisma orientale, eucommia bark, rhizoma gastrodiae, and clematis chinensis as raw materials. According to different physical properties of raw materials, the raw materials are processed respectively and are ground into 120 meshes as well as are sterilized, and therefore, the drug is made. The pulvis and the capsules of the invention are added with an amount of honey to be made into pills. The prescription and the preparation method of the invention are unique and have evident effects on the rheumatic disease.
PURPOSE:To obtain the titled external drug having excellent transcutaneous absorbability, low skin irritation and strong anti-inflammatory analgesic effect, by using indomethacin as a principal drug and 1-dodecylazacycloheptan-2-one as a transcutaneous absorbefacient and dispersing and suspending the agents in water. CONSTITUTION:The objective drug can be produced by using indomethacin as a principal drug and 1-dodecylazacycloheptan-2-one as a transcutaneous absorbefacient and dispersing and suspending the agents in water. Preferably, the drug is further incorporated with an oil or fat such as castor oil, vitelli oil, liquid paraffin, etc. The addition of oil or fat remarkably improves the stability of indomethacin. The contents of indomethacin, 1- dodecylazacycloheptan-2-one, water and the oil or fat are 0.5-5wt%, 0.5-10wt%, 40-95wt% and 0-50wt%, especially 0.5-30wt%, respectively. The titled external drug may be compounded further with a dispersing agent such as surfactant, glycerol, etc.
One of the most severe adverse effects is hyperkalemia (see CONTRAINDICATIONS, WARNINGS, and OVERDOSAGE).

There have also been reports of upper and lower gastrointestinal conditions including obstruction, bleeding, ulceration, and perforation (see CONTRAINDICATIONS and WARNINGS). The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals or reducing the amount taken at one time.

Call your doctor for medical advice about side effects.

To report SUSPECTED ADVERSE REACTIONS, contact the manufacturer Adare at 1-877-731-5116 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.